NorthStar awarded $37 million for Mo-99 production

August 30, 2021, 7:01AMNuclear News
NorthStar’s RadioGenix system produces the medical radioisope Mo-99 without the use of uranium. (Photo: NorthStar)

NorthStar Medical Technologies of Beloit, Wis., will receive $37 million under two cooperative agreements with the National Nuclear Security Administration for the production of molybdenum-99 without the use of high-enriched uranium. Considered a critical medical radioisotope, Mo-99 is used in more than 40,000 medical procedures in the United States each day, including the diagnosis of heart disease and cancer.

To continue reading, log in or create a free account!

Related Articles

Taking aim at disease

Radioisotopes target cancer, improve imaging, and have myriad other medical uses

February 16, 2024, 3:02PMNuclear NewsKristi Nelson Bumpus

On August 2, 1946, 1 millicurie of the isotope carbon-14 left Oak Ridge National Laboratory, bound for the Barnard Free Skin and Cancer Hospital in St. Louis, Mo.That tiny amount of the...